

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

XtalPi
晶泰科技
QuantumPharm Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 8 NOVEMBER 2024

Reference is made to the circular (the “**Circular**”) and the notice (the “**EGM Notice**”) of the extraordinary general meeting (the “**EGM**”) of QuantumPharm Inc. (the “**Company**”) dated 24 October 2024.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that as not less than three-fourths of the votes were cast in favour of the proposed resolution, the proposed resolution as set out in the EGM Notice was duly passed by the shareholders (the “**Shareholders**”) of the Company as a special resolution by way of poll at the EGM. The poll results are as follows:

SPECIAL RESOLUTION		Number of votes (Approximate %)	
		For	Against
1.	THAT: (a) subject to and conditional upon the necessary registration and/or filing procedures with the Registrar of Companies in the Cayman Islands being completed, the English name of the Company be changed from “QuantumPharm Inc.” to “XtalPi Holdings Limited” and the dual foreign name of the Company in Chinese “晶泰控股有限公司” be adopted (the “ Proposed Change of Company Name ”); and	2,558,764,362 (100.00%)	0 (0.00%)

	(b) any one of the directors or any one company secretary of the Company be and is hereby authorised to do all such acts and things and execute all documents or make such arrangements including under seal where appropriate, as he/she may, in his/her absolute discretion, consider necessary, desirable or expedient to effect the Proposed Change of Company Name and to attend to any necessary registration and/or filing for and on behalf of the Company.		
--	---	--	--

As at the date of the EGM, the total number of the shares of the Company (the “**Shares**”) in issue was 3,413,523,761 Shares and holders of which were entitled to attend and vote on the proposed resolution at the EGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the proposed resolution at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). QuantumPharm Roc Holdings Limited, the shareholding platform holding 141,273,894 Shares underlying the options granted for the benefit of the grantees under the Company’s pre-IPO incentive plan, shall abstain and have abstained from voting on the resolution at the EGM. Save as disclosed above, no other Shareholder is required to abstain from voting in respect of the proposed resolution at the EGM. No Shareholder has stated his or her intention in the Circular to vote against or to abstain from voting on the proposed resolution at the EGM.

Tricor Investor Services Limited, the Company’s share registrar in Hong Kong, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

Dr. Wen Shuhao, Dr. Ma Jian and Ms. Chan Wing Ki attended the EGM either in person or by electronic means. Dr. Lai Lipeng, Dr. Jiang Yide Alan, Mr. Law Cheuk Kin Stephen and Mr. Chow Ming Sang did not attend the EGM due to their other business engagements.

By order of the Board
QuantumPharm Inc.
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 8 November 2024

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.